Japan moves closer to first clinical application of iPS cells
This article was originally published in Scrip
Executive Summary
A major research institute in Japan is planning to conduct what looks likely to be the first clinical trial worldwide with induced pluripotent stem (iPS) cells, for the treatment of age-related macular degeneration, although the exact timing of the study remains uncertain.